EMEA: PRESS RELEASE - For Immediate Release

The European ME Alliance is a collaboration of 15 Myalgic Encephalomyelitis (ME) organisations in Europe.

EMEA Writes to World Health Organisation

The Disappearance, Continued Absence and Its Consequences of the Enforcement of the ICD-10 G93.3 Within the Linearization of the ICD-11 Public Beta Draft Version

December 2016

EMEA: PRESS RELEASE - For Immediate Release

The European ME Alliance (EMEA) is a collaboration of 13 ME organisations in European countries who have the common aim of promoting biomedical research into Myalgic Encephalomyelitis and increasing awareness of this debilitating neurological disease.

EMEA has written to the World Health Organisation (WHO) with the Alliance's concerns about planned revisions to the classification of ME.'


The current classification for Myalgic Encephalomyelitis (ME) in the WHO Classification of Diseases (ICD-10) is under section G93.3 and lists ME as a neurological illness.

The WHO have set up a Joint Task Force to prepare for the 11th Revision of the International Classification of Diseases (ICD-11) and this is due to be ready by 2018.

From the WHO web site [http://www.who.int/classifications/icd/revision/en/] -

The Joint Task Force (JTF) is the steering group for ICD-11 version for Mortality and Morbidity Statistics (ICD-11-MMS). The JTF provides strategic and technical advice to WHO for the finalization of the ICD-11-MMS development. The input will draw on scientific advice, where recommended by the JTF or WHO. The primary focus of the JTF is to recommend the subset of the ICD-11 foundation that will be included as codes in the ICD-11-MMS, used for international reporting, as well as how to appropriately structure those codes for tabulation and aggregation. The JTF will also provide guidance and support for the development of the ICD-11-MMS reference guide, including mortality and morbidity coding rules, the use of post-coordination in the ICD-11-MMS, and the suitability of the product for use as a classification. The JTF may seek advice, as necessary, from any other project stakeholders, such as the RSG, the vertical TAGs, the WHO-FIC Network, or other identified experts.

EMEA's letter to WHO is shown below.

We will publish WHO's reply as soon as it is available.

Further Information:

  1. dx revision watch

The Disappearance, Continued Absence and Its Consequences of the Enforcement of the ICD-10 G93.3 Within the Linearization of the ICD-11 Public Beta Draft Version

Dear Dr. B. Üstün,

WHO/ICD Revision Coordinator, Project Management Team


The European ME Alliance (EMEA) is a collaboration of European organisations1 supporting patients suffering from Myalgic Encephalomyelitis (sometimes referred to as Chronic Fatigue Syndrome or ME/CFS) all over Europe.

There are estimated to be between 500,000 and 5 million [1] ME-patients in Europe, depending on which diagnostic criteria are used. The number of patients differs so much due to the prevalence rate varying from 0,1 percent to 1,0 percent, or more.

Within the Myalgic Encephalomyelitis community a great deal of concern has been expressed with regard to the development of the WHO ICD-11 classification. Therefore, on behalf of this sizeable group of patients, EMEA would like to address a number of very important issues.


During 2015 an email was sent by EMEA informing the WHO about the difficulties regarding recognition and identification/diagnosing of Myalgic Encephalomyelitis.

Even though the disease is currently classified under ICD-10 G93.3, the majority of clinicians in Europe continue to view Myalgic Encephalomyelitis as a ‘Fatigue Syndrome’ classified under ‘Mental and Behavioural Disorders’ (ICD-10 F48.0).

This can lead to major deleterious consequences for patients, such as problems with treatments or follow-up of the disorder - not to mention the high medical costs at patients own expenses.

Currently the situation looks even worse since all commonly used terms - post viral fatigue syndrome, Myalgic Encephalomyelitis or chronic fatigue syndrome - have been removed from the ICD-11 Public Beta Draft. e - have been removed from the ICD-11 Public Beta Draft. [2, 3]

EMEA is aware of the various issues regarding Myalgic Encephalomyelitis and the fact that the ICD-11 Revision is a work in progress. To fulfil this complicated task regarding this disease EMEA request that the WHO considers and acts upon the following recommendations:

  • Provide a suitable ICD entity title for the disease – Myalgic Encephalomyelitis

  • Determine the right place in the ICD-11 hierarchy for Myalgic Encephalomyelitis
    Under which chapter(s) and parent classes will the terms, post viral fatigue syndrome, Myalgic Encephalomyelitis and chronic fatigue syndrome, currently covered by ICD-10 G93.3, be classified within ICD-11 Revision;

  • Provide a scientific definition
    taking into consideration all scientific research and accepting the recent 2015 assessment by the IOM as a disease;

  • Define exclusions and exclusion terms;

  • Gather clear, understandable and scientifically valid knowledge domains
    such as constellation of signs and symptoms, severity and course, as well as genetic and other information. Completed with imaging, lab- and other test results, known causes, micro-organisms, medications or genomics linkages;

  • Capture the functional impact of Myalgic Encephalomyelitis
    using the International Classification Functioning Disability and Health (ICF). Quality of life in Myalgic Encephalomyelitis is significantly lower than quality of life in other disorders. [4, 5] This should be indicated in the ICD-11, making it possible for patients to access the necessary benefits;

The endorsement of world-wide accepted diagnostic criteria would be a huge step forward for Myalgic Encephalomyelitis patients, healthcare professionals, health care and research into Myalgic Encephalomyelitis. It would make gathering of valid data and real economic cost estimates to society and patients possible. But mostly it would offer early care and maybe the possibility for diagnosis which can reduce the burden of stigma for Myalgic Encephalomyelitis patients.

A statement has been made that there was ‘no proposal’ to classify the ICD-10 G93.3 legacy terms, post viral fatigue syndrome, Myalgic Encephalomyelitis and chronic fatigue syndrome, under Chapter 07 ‘Mental and Behavioural disorders’.

Looking at the ICD-11 Public Beta Draft, it is clear that the term ‘Bodily Distress Disorder (BDS)’, defined very broadly, leaves much room and real possibility for including non-psychiatric disorders in this entity – and this must not be allowed to happen with regard to Myalgic Encephalomyelitis.

In light of this aspect EMEA wishes to express its deepest concern regarding the absence of the ICD-10 G93.3 legacy terms in the exclusions of BDS.

Also looking at the definition of Chronic Fatigue Syndrome used in the ICD-11 Public Beta Draft before 2013:
"Chronic fatigue syndrome is characterized by extreme chronic fatigue of an indeterminate cause, which is disabling and does not improve with rest and that is exacerbated by physical or mental activity”
crucial information is missing which could, in this case, lead to inclusion of psychiatric disorders in the entity.

Taking both these facts into account the chances of classifying and diagnosing Myalgic Encephalomyelitis as a ‘Mental and Behavioural Disorder’ are enormous, highly realistic and very harmful towards Myalgic Encephalomyelitis patients. EMEA calls on the WHO to protect Myalgic Encephalomyelitis patients by classifying the ICD-10 G93.3 legacy terms with the utmost care and at its rightful place in Chapter 09: Diseases of the nervous system, where it has always been.


EMEA acknowledges that the use of the ICD-11 will be an enlargement and improvement of the International Classifications of Diseases also for patients. But before getting there, a number of issues have to be addressed:

Including PVFS/Benign Myalgic Encephalomyelitis in the ICD-11:

  • Since February 2013 the ICD title term ‘Chronic Fatigue Syndrome’ (CFS), the inclusion term ‘Benign Myalgic Encephalomyelitis’ (BME) and the term in the synonym list ‘Postviral Fatigue Syndrome’ (PVFS), can no longer be found in the ICD-11 Public Beta Draft.
    Is it possible to clarify -
    • On which basis the decision was made to remove these terms from the draft?
    • Is there any intent from the WHO ICD-11 Revision Team to restore these (PVFS, BME, CFS) in the ICD-11 Revision to enable comments, remarks and additions?
      • If yes, when?
      • If not, what is the reason for that decision?
  • EMEA has noticed that the parent page “Certain specified disorders of the nervous system (9H8Y - Other …, 9H8Z - Unspecified)”, the ICD-11 Entity equivalent for the ICD-10 G90-G99, has been removed.
    • Will this parent page be replaced by another page or will different diseases be added to the other pages.
    • Will the terms Postviral Fatigue Syndrome (PVFS), Benign Myalgic Encephalomyelitis (BME) and Chronic Fatigue Syndrome (CFS) be classified under chapter 08/ Diseases of the nervous system or anywhere else?
    • Which term will be the title term, which the inclusion term and the synonym?
    • To which term is the definition and other content parameters going to be assigned to?
    • Are diagnostic criteria going to be included?
    • Where will the definition be based on?
    • Will the current definition be used again?
  • EMEA also read a study about Functional Disorders,
    • will this be the category where Myalgic Encephalomyelitis will be classified under “Functional Disorders” within the Neurology section?


EMEA would like to collaborate with the WHO towards increasing awareness and understanding of Myalgic Encephalomyelitis, set up inter- and multidisciplinary collaboration among different partners (researchers, clinicians, care facilities, patients, family, policymakers, etc.) and provide appropriate care at all levels, as well as research and training for everyone involved with Myalgic Encephalomyelitis. This could improve the lives of Myalgic Encephalomyelitis patients and reduce the burden whilst there is no evidence-based treatment available yet.

Sometimes patients get treated as psychiatric patients and kept in psychiatric wards against their will with no attention to their physical needs. In some cases even comorbidities are being ignored leading to further deterioration of the patient’s general health. Recent European studies also show that Myalgic Encephalomyelitis patients have the poorest quality of life compared to other chronic diseases.

Recent biomedical research has produced hope for treatments to be developed. For example, B cell depletion therapy has shown promising evidence with response rates of two thirds. [6, 7] Also a 2016 study shows that mitochondrial DNA variants correlate with symptoms in Myalgic Encephalomyelitis.[8]

For decades this serious and debilitating disease has been stigmatized [9] due to a lack of application of correct scientific and ethical competence resulting in severe harm being inflicted on ME patients. This stigmatization has allowed misinformation to be perpetuated causing a lack of recognition of this serious and debilitating disease. Patients have had to deal with disbelief and trivialisation of their illness.

This leads to mis- or missed diagnoses and either mistreatment or no treatment. It also leads to insufficient data being collated regarding the illness - not only with regard to the medical needs but also in determining just how many patients there really are and how big the impact is on society, health care, patients and their families.

Due to the effects of this disorder it is almost impossible for patients to campaign for their rights. Within EMEA’s member organisations there are volunteers who have Myalgic Encephalomyelitis themselves or have family members with Myalgic Encephalomyelitis so they know first-hand what it is like to have the disease and live with its limitations. The WHO and the WHO ICD-11 can improve this situation by providing a scientific framework with valuable, reliable and validated information.

EMEA wish to thank you for your time and response to the posed questions and is looking forward to hearing from you.

We reiterate our offer to work with the WHO to effect progress in treating Myalgic Encephalomyelitis. However, we are determined not to compromise on these most serious questions. Myalgic Encephalomyelitis has for far too long been left to the machinations of vested interests who have manipulated the disease and changed the correct perception of the disease, thus diverting research funding to flawed research. This cannot be allowed to continue,

Yours sincerely,

The Board and Members

The European Myalgic Encephalomyelitis Alliance (EMEA)

1 European organisations in 13 Member States: Belgium, Denmark, Finland, Germany, The Netherlands, Ireland, Italy, Spain, Sweden, the UK and Norway, Switzerland and Iceland. (http://www.euro-me.org/about.htm)


1. EUROPEAN COMMISSION - EUROSTAT, Number of European citizens on January 2016, (http://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=tps00001&plugin=1)

2. WORLD HEALTH ORGANISATION, Diseases of the nervous system, G93.3. ICD-10 version.2016, *Postviral Fatigue Syndrome (PVFS), *Benign Myalgic Encephalomyelitis (BME), *Chronic Fatigue Syndrome (CFS) (http://apps.who.int/classifications/icd10/browse/2016/en#/G93.3)

3. WORLD HEALTH ORGANISATION, ICD-11 Beta Draft (Joint Linearization for Mortality and Morbidity Statistics,


4. NACUL, L.C., E. M. Lacerda, P. Campion, D. Pheby, M.D.L. Drachler, J. C. Leite, F. Poland, A. Howe, S. Fayyaz, M. Molokhia. 2011. The functional status and wellbeing of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers.


5. HVIDBERG M.F., L. Schouborg Brinth, A.V. Olesen, K.D. Petersen, L.Ehlers. 2015. The Health-Related Quality of life for patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLoS ONE-Open Access 10(7):e0132421.


6. FLUGE Ø., Bruland O, Risa K, Storstein A, Kristofferson EK, Sapkota D, et al. (2011) Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study. PLoS One 6: e26358. doi: 10.1371/journal.pone.0026358. pmid:22039471 (http://www.ncbi.nlm.nih.gov/pubmed?term=22039471)

7. FLUGE Ø., Mella Olav, K. Risa, S. Lunde, K. Alme, I.G. Rekeland, D. Sapkota, EK Kristofferson, K. Sørland, O. Bruland, O. Dalh. 2015. B-Lymphocyte Depletion in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. PloS ONE- Open Access 10(7): e0129898. (http://journals.plos.org/plosone/article/asset?id=10.1371/journal.pone.0129898.PDF7).

8. BILLING-ROSS P., 2016, Mitochondrial DNA variants correlate with symptoms in MYALGIC ENCEPHALOMYELITIS, Journal of Translational Medicine,


9. Patient survey performed by Matilde Leonardi and commissioned by the European Federation of Neurological Associations (EFNA) revealed that work related stigma in PVFS-BME is 28%, social stigma 44% and feeling of bad wellbeing 30% of the participating patient population.


Return to News

Last Update: December 2016